126 related articles for article (PubMed ID: 35498385)
1. Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report.
Denault MH; Kuang S; Shokoohi A; Leung B; Liu M; Berthelet E; Laskin J; Sun S; Zhang T; Melosky B; Ho C
JTO Clin Res Rep; 2022 May; 3(5):100316. PubMed ID: 35498385
[TBL] [Abstract][Full Text] [Related]
2. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.
Nassar AH; Kim SY; Aredo JV; Feng J; Shepherd F; Xu C; Kaldas D; Gray JE; Dilling TJ; Neal JW; Wakelee HA; Liu Y; Lin SH; Abuali T; Amini A; Nie Y; Patil T; Lobachov A; Bar J; Fitzgerald B; Fujiwara Y; Marron TU; Thummalapalli R; Yu H; Owen DH; Sharp J; Farid S; Rocha P; Arriola E; D'Aiello A; Cheng H; Whitaker R; Parikh K; Ashara Y; Chen L; Sankar K; Harris JP; Nagasaka M; Ayanambakkam A; Velazquez AI; Ragavan M; Lin JJ; Piotrowska Z; Wilgucki M; Reuss J; Luders H; Grohe C; Baena Espinar J; Feiner E; Punekar SR; Gupta S; Leal T; Kwiatkowski DJ; Mak RH; Adib E; Naqash AR; Goldberg SB
J Thorac Oncol; 2024 Jan; ():. PubMed ID: 38278303
[TBL] [Abstract][Full Text] [Related]
3. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.
Faivre-Finn C; Vicente D; Kurata T; Planchard D; Paz-Ares L; Vansteenkiste JF; Spigel DR; Garassino MC; Reck M; Senan S; Naidoo J; Rimner A; Wu YL; Gray JE; Özgüroğlu M; Lee KH; Cho BC; Kato T; de Wit M; Newton M; Wang L; Thiyagarajah P; Antonia SJ
J Thorac Oncol; 2021 May; 16(5):860-867. PubMed ID: 33476803
[TBL] [Abstract][Full Text] [Related]
4. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study.
Desilets A; Blanc-Durand F; Lau S; Hakozaki T; Kitadai R; Malo J; Belkaid W; Richard C; Messaoudene M; Cvetkovic L; Kazandjian S; Tehfe M; Florescu M; Jao K; Daaboul N; Owen S; Shieh B; Agulnik J; Cohen V; Charbonneau C; Marcoux N; Blais N; Leighl NB; Bradbury PA; Liu G; Shepherd FA; Bahig H; Routy B; Sacher A; Elkrief A
Eur J Cancer; 2021 Jan; 142():83-91. PubMed ID: 33242835
[TBL] [Abstract][Full Text] [Related]
5. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.
Gray JE; Villegas A; Daniel D; Vicente D; Murakami S; Hui R; Kurata T; Chiappori A; Lee KH; Cho BC; Planchard D; Paz-Ares L; Faivre-Finn C; Vansteenkiste JF; Spigel DR; Wadsworth C; Taboada M; Dennis PA; Özgüroğlu M; Antonia SJ
J Thorac Oncol; 2020 Feb; 15(2):288-293. PubMed ID: 31622733
[TBL] [Abstract][Full Text] [Related]
6. Chemoradiation followed by adjuvant durvalumab in stage III non-small cell lung cancer: Real-world comparison of treatment outcomes to historical controls treated with chemoradiation alone.
Saad A; Goldstein J; Appel S; Daher S; Urban D; Onn A; Gantz-Sorotsky H; Lobachov A; Gottfried T; Spieler B; Bar J
Thorac Cancer; 2022 Jun; 13(12):1763-1771. PubMed ID: 35538909
[TBL] [Abstract][Full Text] [Related]
7. A study of the efficacy and toxicity outcomes of extended durvalumab dosing in patients with stage III unresectable non-small cell lung cancer (NSCLC) during the COVID-19 pandemic.
Hanna L; Moffat GT; Hopman W; Gaudreau PO; Fung AS
Cancer Treat Res Commun; 2023; 34():100678. PubMed ID: 36608489
[TBL] [Abstract][Full Text] [Related]
8. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
Taugner J; Käsmann L; Eze C; Rühle A; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
Invest New Drugs; 2021 Aug; 39(4):1189-1196. PubMed ID: 33704621
[TBL] [Abstract][Full Text] [Related]
9. Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab.
Jazieh K; Khorrami M; Saad A; Gad M; Gupta A; Patil P; Viswanathan VS; Rajiah P; Nock CJ; Gilkey M; Fu P; Pennell NA; Madabhushi A
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35256515
[TBL] [Abstract][Full Text] [Related]
10. Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer.
Hassanzadeh C; Sita T; Savoor R; Samson PP; Bradley J; Gentile M; Roach M; Mohindra N; Waqar S; Kruser TJ; Robinson C
J Thorac Dis; 2020 Nov; 12(11):6690-6700. PubMed ID: 33282370
[TBL] [Abstract][Full Text] [Related]
11. Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP).
Faehling M; Schumann C; Christopoulos P; Hoffknecht P; Alt J; Horn M; Eisenmann S; Schlenska-Lange A; Schütt P; Steger F; Brückl WM; Christoph DC
Lung Cancer; 2020 Dec; 150():114-122. PubMed ID: 33126091
[TBL] [Abstract][Full Text] [Related]
12. Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab.
Jazieh K; Gad M; Saad A; Wei W; Pennell NA
Transl Lung Cancer Res; 2021 Jul; 10(7):3071-3078. PubMed ID: 34430348
[TBL] [Abstract][Full Text] [Related]
13. Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
Shukla NA; Althouse S; Meyer Z; Hanna N; Durm G
Clin Lung Cancer; 2021 Jul; 22(4):274-281. PubMed ID: 33610454
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study).
Tanzawa S; Ushijima S; Shibata K; Shibayama T; Bessho A; Kaira K; Misumi T; Shiraishi K; Matsutani N; Tanaka H; Inaba M; Haruyama T; Nakamura J; Kishikawa T; Nakashima M; Iwasa K; Fujiwara K; Kohyama T; Kuyama S; Miyazawa N; Nakamura T; Miyawaki H; Ishida H; Oda N; Ishikawa N; Morinaga R; Kusaka K; Fujimoto N; Yokoyama T; Gemba K; Tsuda T; Nakagawa H; Ono H; Shimizu T; Nakamura M; Kusumoto S; Hayashi R; Shirasaki H; Ochi N; Aoe K; Kanaji N; Kashiwabara K; Inoue H; Seki N
Ther Adv Med Oncol; 2021; 13():1758835921998588. PubMed ID: 33717228
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer.
Schmid S; Garcia M; Cheng S; Zhan L; Chotai S; Balaratnam K; Khan K; Patel D; Catherine Brown M; Sachdeva R; Xu W; Shepherd FA; Sacher A; Leighl NB; Bradbury P; Moriarty P; Sara Kuruvilla M; Liu G
Lung Cancer; 2022 Apr; 166():58-62. PubMed ID: 35183992
[TBL] [Abstract][Full Text] [Related]
16. Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP).
Raez LE; Arrieta O; Chamorro DF; Soberanis-Piña PD; Corrales L; Martín C; Cuello M; Samtani S; Recondo G; Mas L; Zatarain-Barrón ZL; Ruíz-Patiño A; García-Robledo JE; Ordoñez-Reyes C; Jaller E; Dickson F; Rojas L; Rolfo C; Rosell R; Cardona AF
Front Oncol; 2022; 12():904800. PubMed ID: 35903685
[TBL] [Abstract][Full Text] [Related]
17. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.
Senan S; Özgüroğlu M; Daniel D; Villegas A; Vicente D; Murakami S; Hui R; Faivre-Finn C; Paz-Ares L; Wu YL; Mann H; Dennis PA; Antonia SJ
ESMO Open; 2022 Apr; 7(2):100410. PubMed ID: 35247871
[TBL] [Abstract][Full Text] [Related]
18. Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.
Aredo JV; Mambetsariev I; Hellyer JA; Amini A; Neal JW; Padda SK; McCoach CE; Riess JW; Cabebe EC; Naidoo J; Abuali T; Salgia R; Loo BW; Diehn M; Han SS; Wakelee HA
J Thorac Oncol; 2021 Jun; 16(6):1030-1041. PubMed ID: 33588109
[TBL] [Abstract][Full Text] [Related]
19. Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer.
Preti BTB; Sanatani MS; Breadner D; Lakkunarajah S; Scott C; Esmonde-White C; McArthur E; Rodrigues G; Chaudhary M; Mutsaers A; Sachdeva R; Vincent MD
Curr Oncol; 2023 Aug; 30(8):7713-7721. PubMed ID: 37623040
[TBL] [Abstract][Full Text] [Related]
20. A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer.
Bruni A; Scotti V; Borghetti P; Vagge S; Cozzi S; D'Angelo E; Giaj Levra N; Fozza A; Taraborrelli M; Piperno G; Vanoni V; Sepulcri M; Trovò M; Nardone V; Lattanzi E; Bou Selman S; Bertolini F; Franceschini D; Agustoni F; Jereczek-Fossa BA; Magrini SM; Livi L; Lohr F; Filippi AR
Front Oncol; 2021; 11():744956. PubMed ID: 34650927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
